Monday - May 25, 2026

Biopreservation Market to Grow at a CAGR of ~7.5% Driven by Rising Demand in Cell & Gene Therapies and Organ Transplantation | DelveInsight

Biopreservation Market The biopreservation market is growing rapidly, driven by increased adoption of cell and gene therapies, rising organ transplantation demand, and the need for advanced preservation solutions for biologics and vaccines. With the rise of chronic diseases and advances … Continue reading

Groundbreaking Auburn University Research Reveals Key Advances in Managing Feline Weight and Health, Research Underwritten by EveryCat Health Foundation and Leading Grant Organizations

Auburn University Research Advancing Feline Obesity Management Funded by EveryCatHealth Foundation, Nestle Research and Auburn University’s Intramural Grant Program and Scott-Ritchey Research Center Wyckoff, New Jersey – A groundbreaking study conducted by Auburn University’s College of Veterinary Medicine, funded in … Continue reading

Excessive Daytime Sleepiness Pipeline Insight 2025: Amneal’s FDA Approval of Sodium Oxybate Oral Solution, Novel Orexin Agonists, and Next-Generation Sleep-Wake Modulators Redefine Narcolepsy Care | D

Excessive Daytime Sleepiness Pipeline Excessive Daytime Sleepiness (EDS) is a key symptom of narcolepsy, obstructive sleep apnea, idiopathic hypersomnia, and other neurological disorders. It causes overwhelming fatigue, sudden sleep attacks, and cognitive impairment, significantly affecting daily life and safety. Current … Continue reading

Acute Myeloid Leukemia Pipeline Insight 2025: Akeso’s FDA ODD for Ligufalimab, 100+ Companies Advancing Targeted, Immune, and Cell-Based Therapies | DelveInsight

Acute Myeloid Leukemia Pipeline Insight The acute myeloid leukemia (AML) treatment pipeline is undergoing a profound transformation, with innovative therapies advancing beyond traditional chemotherapy toward precision, immune-based, and regenerative approaches. AML, an aggressive hematologic malignancy, continues to present high relapse … Continue reading

Dystrophic Epidermolysis Bullosa Pipeline Insight 2025: Krystal Biotech’s FDA Label Expansion for VYJUVEK, Emerging Gene Therapies and Regenerative Approaches Drive Innovation | DelveInsight

Dystrophic epidermolysis bullosa is a rare and debilitating genetic skin disorder characterized by extreme skin fragility, painful blistering, chronic wounds, and risk of scarring and squamous cell carcinoma. For decades, treatment options were largely limited to supportive wound care, pain … Continue reading